Novartis Stopping Work on Branaplam as Oral SMA Therapy & 31 Days of SMA

SMA News Today’s multimedia associate, Price Wooldridge, discusses Novartis stopping work on the development of Branaplam as an oral treatment for Spinal Muscular Atrophy (SMA).Forums Director Kevin Schaefer reads a story from our 31 Days of SMA series. This piece, written by Alvaro Cheherlian, is about being an entrepreneur with SMA.Link to 31 Days of SMA series: https://smanewstoday.com/category/31-days-of-sma/ Are you interested in learning more about spinal muscular atrophy? If so, please visit https://smanewstoday.com/